太龙药业：8月15日召开董事会会议

Group 1 - The core point of the article is that Tai Long Pharmaceutical (SH 600222) held its first board meeting of the tenth session on August 15, 2025, to discuss the appointment of the board secretary and other documents [2] - For the year 2024, the revenue composition of Tai Long Pharmaceutical is as follows: 79.38% from pharmaceutical manufacturing, 13.65% from pharmaceutical research and development, 6.71% from pharmaceutical distribution, and 0.27% from other businesses [2]